ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

NEW YORK, Oct. 3, 2024 /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the "Class Period"), of the important October 15, 2024 lead plaintiff deadline.

So what: If you purchased Ardelyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Ardelyx class action, go to https://rosenlegal.com/submit-form/?case_id=2125 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 15, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Details of the case: According to the lawsuit, during the Class Period, defendants made materially false and misleading statements regarding Ardelyx's future revenue and funding requirements, and the commercial success of a phosphorus inhibitor, XPHOZAH. Among other things, Ardelyx would apply to include XPHOZAH in the Transitional Drug Add-on Payment Adjustment program ("TDAPA") when in fact, Ardelyx had not yet reached a firm decision concerning whether or not to apply to include XPHOZAH in TDAPA. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ardelyx class action, go to https://rosenlegal.com/submit-form/?case_id=2125 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.